Hansa Biopharma AB (publ) (LON:0RC7)

London · Delayed Price · Currency is GBP · Price in SEK

26.80

-0.46 (-1.69%)

At close: Jul 11, 2025

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2016 - 2018
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2016 - 2018
Antibody-cleaving Enzyme Technology Platform	134.09M	Log In	Log In	Log In	Log In	Upgrade
Antibody-cleaving Enzyme Technology Platform Growth	-13.22%	Log In	Log In	Log In	Log In	Upgrade

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2016 - 2018
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2016 - 2018
Europe (excluding Sweden)	106.68M	Log In	Log In	Log In	Log In	Upgrade
Europe (excluding Sweden) Growth	24.66%	Log In	Log In	Log In	Log In	Upgrade
North America	27.42M	Log In	Log In	Log In	Log In	Upgrade
North America Growth	-57.34%	Log In	Log In	Log In	Log In	Upgrade
Sweden	-	Log In	Log In	Log In	Log In	Upgrade
Sweden Growth	-	Log In	Log In	Log In	Log In	Upgrade